Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients

It is widely accepted that assessing circular tumor DNA (ctDNA) in the plasma of cancer patients is a promising practice to evaluate somatic mutations from solid tumors noninvasively. Recently, it was reported that isolation of extracellular vesicles improves the detection of mutant DNA from plasma...

Full description

Saved in:
Bibliographic Details
Main Authors: Silvia Galbiati (Author), Francesco Damin (Author), Dario Brambilla (Author), Lucia Ferraro (Author), Nadia Soriani (Author), Anna M. Ferretti (Author), Valentina Burgio (Author), Monica Ronzoni (Author), Riccardo Vago (Author), Laura Sola (Author), Marcella Chiari (Author)
Format: Book
Published: MDPI AG, 2021-02-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3feae5b1496e4210b4bb95cb4b0f7cd7
042 |a dc 
100 1 0 |a Silvia Galbiati  |e author 
700 1 0 |a Francesco Damin  |e author 
700 1 0 |a Dario Brambilla  |e author 
700 1 0 |a Lucia Ferraro  |e author 
700 1 0 |a Nadia Soriani  |e author 
700 1 0 |a Anna M. Ferretti  |e author 
700 1 0 |a Valentina Burgio  |e author 
700 1 0 |a Monica Ronzoni  |e author 
700 1 0 |a Riccardo Vago  |e author 
700 1 0 |a Laura Sola  |e author 
700 1 0 |a Marcella Chiari  |e author 
245 0 0 |a Small EVs-Associated DNA as Complementary Biomarker to Circulating Tumor DNA in Plasma of Metastatic Colorectal Cancer Patients 
260 |b MDPI AG,   |c 2021-02-01T00:00:00Z. 
500 |a 10.3390/ph14020128 
500 |a 1424-8247 
520 |a It is widely accepted that assessing circular tumor DNA (ctDNA) in the plasma of cancer patients is a promising practice to evaluate somatic mutations from solid tumors noninvasively. Recently, it was reported that isolation of extracellular vesicles improves the detection of mutant DNA from plasma in metastatic patients; however, no consensus on the presence of dsDNA in exosomes has been reached yet. We analyzed small extracellular vesicle (sEV)-associated DNA of eleven metastatic colorectal cancer (mCRC) patients and compared the results obtained by microarray and droplet digital PCR (ddPCR) to those reported on the ctDNA fraction. We detected the same mutations found in tissue biopsies and ctDNA in all samples but, unexpectedly, in one sample, we found a <i>KRAS</i> mutation that was not identified either in ctDNA or tissue biopsy. Furthermore, to assess the exact location of sEV-associated DNA (outside or inside the vesicle), we treated with DNase I sEVs isolated with three different methodologies. We found that the DNA inside the vesicles is only a small fraction of that surrounding the vesicles. Its amount seems to correlate with the total amount of circulating tumor DNA. The results obtained in our experimental setting suggest that integrating ctDNA and sEV-associated DNA in mCRC patient management could provide a complete real-time assessment of the cancer mutation status. 
546 |a EN 
690 |a exosomes 
690 |a extracellular vesicles 
690 |a liquid biopsy 
690 |a cancer biomarkers 
690 |a ddPCR 
690 |a microarray 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 14, Iss 2, p 128 (2021) 
787 0 |n https://www.mdpi.com/1424-8247/14/2/128 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/3feae5b1496e4210b4bb95cb4b0f7cd7  |z Connect to this object online.